GEN Exclusives

More »

GEN News Highlights

More »
Jul 8, 2010

iPierian Secures $22M to Bolster iPSC-Based Drug Discovery

  • iPierian, a company using patient-derived induced pluripotent stem cells (iPSCs) for drug discovery, closed a $22 million Series B equity financing. The money will allow the company to drive its programs into the clinic while securing pharmaceutical partnerships.

    “The company has created a remarkable opportunity to integrate massive amounts of imaging, genomic, molecular, and clinical data in a way that will dramatically improve the drug discovery and development process,” according to Krishna Yeshwant, M.D., partner at Google Ventures, which was one of the new investors for this round. Dr. Yeshwant will join the iPierian board of directors.

    The Series B funding brings the total amount of equity capital raised by iPierian to $54 million since its inception in 2007. The company is developing and applying cellular reprogramming and differentiation technologies to harness the power of pluripotent stem cells for the discovery and development of small molecules or biologics.

    Its initial focus is on neurodegenerative diseases including spinal muscular atrophy, amyotrophic lateral sclerosis, and Parkinson disease. In addition, iPierian has a therapeutic program intended for partnering in metabolic disease.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?